"Comment 
Number",Ballot,Chapter,Section,Page #,Line #,Artifact ID,Resource(s),HTML Page name(s),URL,Vote and Type,Sub-category,Tracker #,Existing Wording,Proposed Wording,Ballot Comment,Summary,In person resolution requested,Comment grouping,Schedule,Triage Note,Pubs,Disposition WG,Disposition,Disposition Comment or Retract/Withdraw details,Disposition/Retract/ Withdrawal Date,Mover / seconder,For ,Against,Abstain,Retracted / Withdrawn,Disposition External Organization,Responsible Person,Change Applied,Substantive Change,Submitted By,Organization,On behalf of,Commenter Email,Submitter Tracking ID,Referred To,Received From,Notes,,
1,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerPrimaryTumorClassification-model.html,NEG,Correction,,"Code representing the size and extent of the primary tumor, based on criteria defined by the staging system being used.",,"Isn't this coding a pre-coordination of several characteristics of the tumor, node, metastasis or suffix?  ",pre-coordination,,,,,,,,,,,,,,,,,,,Amnon Shabo (Shvo) ,Philips ,,,,,,,,
2,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-StageSuffix-model.html,NEG,Correction,,"Code representing a suffix used in conjuction with certain breast cancer stages, based on criteria defined by the staging system being used.",,"Isn't this coding a pre-coordination of several characteristics of the tumor, node, metastasis or suffix?  ",pre-coordination,Yes,,,,,,,,,,,,,,,,,,Amnon Shabo (Shvo) ,Philips ,,,,,,,,
3,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerRegionalNodesClassification-model.html,NEG,Correction,,"Code representing the presence of metastases in regional lymph nodes, based on criteria defined by the staging system being used.",,"Isn't this coding a pre-coordination of several characteristics of the tumor, node, metastasis or suffix?  ",pre-coordination,Yes,,,,,,,,,,,,,,,,,,Amnon Shabo (Shvo) ,Philips ,,,,,,,,
4,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerDistantMetastasesClassification-model.html,NEG,Correction,,"Code representing the presence of distant metastases, based on criteria defined by the staging system being used.",,"Isn't this coding a pre-coordination of several characteristics of the tumor, node, metastasis or suffix?  ",pre-coordination,Yes,,,,,,,,,,,,,,,,,,Amnon Shabo (Shvo) ,Philips ,,,,,,,,
5,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerPrimaryTumorClassification-model.html,NEG,Correction,,"Note: it is not clear if Interpretation belongs in FindingTopic, rather than a context class, but that is how CIMI has modeled it.",,"Not sure what ""belongs"" means in this note taken from FHIR StructureDefinition of BreastCancerPrimaryTumorClassificationModel, but in any case, interpretation in specialty domains like oncology should always be separated from what it interprets, so that the association between the two are semantically characterized and the metadata of the interpretation is properly captured (like time, method, performer, etc).",Interpretation and Finding,Yes,,,,,,,,,,,,,,,,,,Amnon Shabo (Shvo) ,Philips ,,,,,,,,
6,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/ValueSet-oncology-BreastCancerTypeVS.html,A-Q,,,Histologic types of breast cancer. Codes are drawn from ICD-O-3. Codes are presented as local codes due to the lack of a ICD-O-3 terminology server available to the FHIR IG publisher.,,"What does it mean ""available to the FHIR IG publisher"" and why should it be a motivation to create a local code system?",local code system,No,,,,,,,,,,,,,,,,,,Amnon Shabo (Shvo) ,Philips ,,,,,,,,
7,2018-May Breast Cancer,,,,,,,,,NEG,,16143,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
8,2018-May Breast Cancer,,,,,,,,,NEG,,16144,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
9,2018-May Breast Cancer,,,,,,,,,A-Q,,16163,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
10,2018-May Breast Cancer,,,,,,,,,A-Q,,16166,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
11,2018-May Breast Cancer,,,,,,,,,NEG,,16167,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
12,2018-May Breast Cancer,,,,,,,,,NEG,,16168,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
13,2018-May Breast Cancer,,,,,,,,,NEG,,16169,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
14,2018-May Breast Cancer,,,,,,,,,NEG,,16170,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
15,2018-May Breast Cancer,,,,,,,,,NEG,,16176,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
16,2018-May Breast Cancer,,,,,,,,,NEG,,16178,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
17,2018-May Breast Cancer,,,,,,,,,NEG,,16179,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
18,2018-May Breast Cancer,,,,,,,,,A-S,,16181,,,,,,,,,,,,,,,,,,,,,,,Claude Nanjo ,University of Utah ,,,,,,,,
19,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerPresenceStatement-model.html,A-A,,,,,The author's comments do make sense,The author's comments do make sense,Yes,,,,,,,,,,,,,,,,,,Greg Staudenmaier  ,US Department of Veterans Affairs ,Keith Salzman  ,keith.salzman@bookzurman.com ,,,,,,
20,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-EstrogenReceptorStatus-model.html,A-A,,,,,Agree to use Interpretation vice value,Agree to use Interpretation vice value,Yes,,,,,,,,,,,,,,,,,,Greg Staudenmaier  ,US Department of Veterans Affairs ,Keith Salzman  ,keith.salzman@bookzurman.com ,,,,,,
21,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-HER2ReceptorStatus-model.html,A-A,,,,,Agree to use Interpretation vice value,Agree to use Interpretation vice value,Yes,,,,,,,,,,,,,,,,,,Greg Staudenmaier  ,US Department of Veterans Affairs ,Keith Salzman  ,keith.salzman@bookzurman.com ,,,,,,
22,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-HER2ReceptorStatus-model.html,A-A,,,,,"On the question of using a single score, I would defer tot the specialists","On the question of using a single score, I would defer tot the specialists",Yes,,,,,,,,,,,,,,,,,,Greg Staudenmaier  ,US Department of Veterans Affairs ,Keith Salzman  ,keith.salzman@bookzurman.com ,,,,,,
23,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/index.html,A-A,,,,,"2.Are there other initiatives or projects that also deal with cross-cutting data standards for breast cancer that should be taken into account?  
Yes.  Please review the CDISC Breast Cancer TAUG (Therapeutic Area User Guide), co-developed with TransCelerate Biopharma, C-Path, FDA and NCI. ","Please review the CDISC Breast Cancer TAUG (Therapeutic Area User Guide), co-developed with TransCelerate Biopharma, C-Path, FDA and NCI. ",,,,,,,,,,,,,,,,,,,Mitra Rocca ,Food and Drug Administration ,,,,,,,,
24,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/index.html,A-A,,,,,Another initiative to look at is the OHDSI's oncology WG and their efforts in extending their Common Data Model (CDM) to include oncology concepts. ,Another initiative to look at is the OHDSI's oncology WG and their efforts in extending their Common Data Model (CDM) to include oncology concepts. ,,,,,,,,,,,,,,,,,,,Mitra Rocca ,Food and Drug Administration ,,,,,,,,
25,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerHistologicGrade.html,NEG,Correction,,Binding: NottinghamCombinedGradeVS (required),<create new value set for morphology scores>,"Incorrect to bind components' values for TubuleFormationScore, NuclearPleomorphismScore,  MitoticCountScore to NottinghamCombinedGradeVS, need a new morphology score value set for those. Only the overall resource's .valueCodeableConcept should be bound to NottinghamCombinedGradeVS.",Need a new morphology score value set for component score value bindings.,,,,,,,,,,,,,,,,,,,Nell Lapres ,Epic ,Daniel Rutz ,drutz@epic.com ,,,,,,
26,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerHistologicGrade.html,NEG,Correction,,Binding: ExceptionValueVS (required),<specify only an appropriate subset of the current data absent reasons>,"DataAbsentReason needs to further constrain the options in the CIMI ExceptionValueVS, as there are too many possible options which are inappropriate and would be difficult to map to the appropriate options (as generally defined by CAP).","Need a subset of only appropriate data absent reason values, current ExceptionValueVS allows many responses that are inappropraite and not reasonable to try mapping to the right ones.",,,,,,,,,,,,,,,,,,,Nell Lapres ,Epic ,Daniel Rutz ,drutz@epic.com ,,,,,,
27,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerHistologicGrade.html,A-S,Enhancement,,,,ValueCodeableConcept is 44648-4  Histologic grade [Score] in Breast cancer specimen Qualitative by Nottingham (https://s.details.loinc.org/LOINC/44648-4.html). The LOINC answer list is normative and contains six values. Three of them are flavors of null but are not included in the CodeableConcept value set. Consider adding them. ,The LOINC answer list is normative and contains six values. Three of them are flavors of null but are not included in the CodeableConcept value set. Consider adding them. ,,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,
28,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-BreastCancerHistologicGrade.html,A-S,Enhancement,,,,This profile contains one LOINC code and four SNOMED observable entity codes consider using and requesting LOINC codes for the four that are missing in LOINC since these are pathology (lab) results.,his profile contains one LOINC code and four SNOMED observable entity codes consider using and requesting LOINC codes for the four that are missing in LOINC since these are pathology (lab) results.,,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,
29,2018-May Breast Cancer,,,,,,ImplementationGuide,,,NEG,Correction,,,,The topic statement should be assertion to align with condition and contain values from the BreastCancerTypeVS. The histologic type for the condition should be a qualifier.,The topic statement should be assertion to align with condition and contain values from the BreastCancerTypeVS. The histologic type for the condition should be a qualifier.,,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,
30,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/ValueSet-oncology-HER2IHCMethodVS.html,A-S,Correction,,,,"I'm using this one as an example but this comment pertains to all observations. I'm also wondering why the method needs to be specified since it is included in the lab observation. If it does need to be specified, method value sets should not contain the observation they quality. For example, for this observation, the method should be 708097004 |Immunohistochemistry technique (qualifier value)| instead of HER2 by ImmunoHistochemistry. "," If it does need to be specified, method value sets should not contain the observation they quality.",,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,
31,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/valuesets.html,A-S,Enhancement,,,,"I wanted to note that one value set has already been created in VSAC that you can use for binding:
Positive Negative
OID:
2.16.840.1.113762.1.4.1166.6
2. 
",I wanted to note that one value set has already been created in VSAC that you can use for binding,,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,
32,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-MammaprintRecurrenceScore-model.html,NEG,Correction,,"Fixed Value: http://ncimeta.nci.nih.gov
Fixed Value: C2827401 ",,"Observations should consistently use LOINC (or SCT if international use) for the code. CIMI, HL7, LOINC need to figure out how to deal with terminologies that are not publicly available. ","Observations should consistently use LOINC (or SCT if international use) for the code. CIMI, HL7, LOINC need to figure out how to deal with terminologies that are not publicly available. ",,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,
33,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/profiles.html,A-C,,," Does it make more sense to report the OncotypeDx as a single score, regardless of the type of cancer?",,I agree with the notion of using a single score for all types of cancer if the meaning is the same.,I agree with the notion of using a single score for all types of cancer if the meaning is the same.,,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,
34,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/profiles.html,A-C,,," Does it make more sense to report the OncotypeDx as a single score, regardless of the type of cancer?",,I agree with the notion of using a single score for all types of cancer if the meaning is the same.,I agree with the notion of using a single score for all types of cancer if the meaning is the same.,,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,
35,2018-May Breast Cancer,,,,,,ImplementationGuide,,http://hl7.org/fhir/us/breastcancer/StructureDefinition-oncology-DistanceToNipple-extension.html,A-S,Clarification,,The body site location in relation to the nipple.,Distance between the body site location of XXX and the nipple.,"Suggesting adding ""From where"" to the name and description of this profile.What body site?  Is this the distance from the tumor? ","Suggesting adding ""From where"" to the name and description of this profile.What body site?  Is this the distance from the tumor? ",,,,,,,,,,,,,,,,,,,Susan Matney ,,,,,,,,,